Cancer treatment: the combination of vaccination with other therapies

Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, 54P4, Herlev Ringvej 75, 2730 Herlev, Denmark.
Cancer Immunology and Immunotherapy (Impact Factor: 3.94). 03/2008; 57(11):1735-43. DOI: 10.1007/s00262-008-0480-y
Source: PubMed

ABSTRACT Harnessing of the immune system by the development of 'therapeutic' vaccines, for the battle against cancer has been the focus of tremendous research efforts over the past two decades. As an illustration of the impressive amounts of data gathered over the past years, numerous antigens expressed on the surface of cancer cells, have been characterized. To this end, recent years research has focussed on characterization of antigens that play an important role for the growth and survival of cancer cells. Anti-apoptotic molecules like survivin that enhance the survival of cancer cells and facilitate their escape from cytotoxic therapies represent prime vaccination candidates. The characterization of a high number of tumor antigens allow the concurrent or serial immunological targeting of different proteins associated with such cancer traits. Moreover, while vaccination in itself is a promising new approach to fight cancer, the combination with additional therapy could create a number of synergistic effects. Herein we discuss the possibilities and prospects of vaccination when combined with other treatments. In this regard, cell death upon drug exposure may be immunogenic or non-immunogenic depending on the specific chemotherapeutics. Also, chemotherapy represents one of several options available for clearance of CD4+ Foxp3+ regulatory T cells. Moreover, therapies based on monoclonal antibodies may have synergistic potential in combination with vaccination, both when used for targeting of tumor cells and endothelial cells. The efficacy of therapeutic vaccination against cancer will over the next few years be studied in settings taking advantage of strategies in which vaccination is combined with other treatment modalities. These combinations should be based on current knowledge not only regarding the biology of the cancer cell per se, but also considering how treatment may influence the malignant cell population as well as the immune system.


Available from: Jürgen C Becker, Jun 09, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The goal of this article is to present basic scientific principles and core algorithms of the simulation module of the CERvical cancer ONCOsimulator (CERONCO) developed within the context of the DrTherapat project (FP7-ICT-600852). CERONCO simulates the response of cervical tumours to radiotherapy treatment (external beam radiotherapy followed by brachytherapy) with concomitant weekly cisplatin, in the patient-individualized context. Results from a preliminary clinical adaptation study based on the MR imaging data of a clinical case are presented as well.
    2014 6th Int. Adv. Res. Workshop on In Silico Oncology and Cancer Investigation – The CHIC Project Workshop (IARWISOCI), Athens, Greece, Nov.3-4, 2014 (www.6thiarwisoci., pp.39-42. (open-access version), ISBN: 978-618-80348-1-5, Athens, Greece; 11/2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the previous years, semantic metadata have largely contributed to the management, exchange and querying of health-related data, including mathematical and computational disease simulation model descriptions, implementations and output results. In this paper, we present a proposal for an abstract semantic metadata infrastructure layout, indicating its modularity, and thus its capability to operate with different combinations of software tools. Its potential contribution for the purposes of the CHIC project is also reported.
    2014 6th Int. Adv. Res. Workshop on In Silico Oncology and Cancer Investigation – The CHIC Project Workshop (IARWISOCI), Athens, Greece, Nov.3-4, 2014 (www.6thiarwisoci., pp.52-55. (open-access version), ISBN: 978-618-80348-1-5, Athens, Greece; 11/2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The induction of active immunity against tumor-associated antigens in order to prevent relapse of cancer is a promising approach but has so far shown only low efficacy. This low efficacy may in part be due to clonal escape of tumor cell variants by downregulation of antigen expression or inflammation-induced dedifferentiation. Identification of novel tumor-associated antigens that at the same time are essential for continued tumor cell survival is thus critical for the development of active cancer vaccinations. At the same time, identification of novel endogenous murine tumor antigens will help improve pre-clinical development of cancer immunotherapy. The anti-apoptotic protein Bcl-xL has been suggested to be such an essential tumor antigen, but the lack of well-defined murine epitopes have delayed preclinical studies of Bcl-xL targeting cancer vaccines. Here, we report the identification of two novel murine tumor-associated epitopes TAYQSFEQV and AFFSFGGAL derived from mouse Bcl-xL. Dendritic cell (DC)-based vaccination induced CD8+ T cells capable of producing IFN-γ upon restimulation with these epitopes. Thus, our data may benefit the design of future immunotherapy strategies by providing a pre-clinical model for cancervaccination with an endogenous tumor antigen which can be combined with other cancer treatments.This article is protected by copyright. All rights reserved.
    Scandinavian Journal of Immunology 05/2014; 80(2). DOI:10.1111/sji.12192 · 1.88 Impact Factor